Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus

Gail Matthews, Eric C Seaberg, Anchalee Avihingsanon, Scott Bowden, Gregory J Dore, Sharon R Lewin, Joe Sasadeusz, Peter Revill, Margaret Littlejohn, Jennifer F Hoy, Robert Finlayson, Kiat Ruxrungtham, Melissa Saulynas, Stephen Locarnini, Chloe L Thio

Research output: Contribution to journalArticleResearchpeer-review

37 Citations (Scopus)

Abstract

Background. Tenofovir (TDF) is effective for treatment of hepatitis B virus (HBV) in human immunodeficiency virus (HIV) infection; however, some individuals have ongoing HBV viremia, the reasons for which are unclear. We determined the patterns and factors associated with detectable HBV DNA in HIV-HBV-coinfected subjects on highly active antiretroviral therapy (HAART).Methods. One hundred sixty-five HIV-HBV-coinfected individuals from the United States, Australia, and Thailand, the majority of whom were on HAART at study entry, were prospectively followed semiannually for a median of 2.8 years. Logistic regression was used to determine factors associated with detectable HBV DNA.Results. Anti-HBV regimens were TDF/emtricitabine (57 ), lamivudine or emtricitabine (19 ), or TDF monotherapy (13 ). During follow-up, HBV DNA was detected at 21 of study visits and was independently associated with hepatitis B e antigen (HBeAg), HAART 1 log from nadir), and viral blips. No TDF resistance was identified.Conclusions. Tenofovir/ emtricitabine was superior to other anti-HBV regimens in long-term HBV suppression. HBV viremia on therapy was identified in 1 of 3 main patterns. Suboptimal adherence was associated with detectable HBV DNA during therapy, even when HIV was undetectable. ? 2012 The Author
Original languageEnglish
Pages (from-to)87 - 94
Number of pages8
JournalClinical Infectious Diseases
Volume56
Issue number9
DOIs
Publication statusPublished - 2013

Cite this

Matthews, Gail ; Seaberg, Eric C ; Avihingsanon, Anchalee ; Bowden, Scott ; Dore, Gregory J ; Lewin, Sharon R ; Sasadeusz, Joe ; Revill, Peter ; Littlejohn, Margaret ; Hoy, Jennifer F ; Finlayson, Robert ; Ruxrungtham, Kiat ; Saulynas, Melissa ; Locarnini, Stephen ; Thio, Chloe L. / Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus. In: Clinical Infectious Diseases. 2013 ; Vol. 56, No. 9. pp. 87 - 94.
@article{307534a5badb4023a81bcb0120e0c38d,
title = "Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus",
abstract = "Background. Tenofovir (TDF) is effective for treatment of hepatitis B virus (HBV) in human immunodeficiency virus (HIV) infection; however, some individuals have ongoing HBV viremia, the reasons for which are unclear. We determined the patterns and factors associated with detectable HBV DNA in HIV-HBV-coinfected subjects on highly active antiretroviral therapy (HAART).Methods. One hundred sixty-five HIV-HBV-coinfected individuals from the United States, Australia, and Thailand, the majority of whom were on HAART at study entry, were prospectively followed semiannually for a median of 2.8 years. Logistic regression was used to determine factors associated with detectable HBV DNA.Results. Anti-HBV regimens were TDF/emtricitabine (57 ), lamivudine or emtricitabine (19 ), or TDF monotherapy (13 ). During follow-up, HBV DNA was detected at 21 of study visits and was independently associated with hepatitis B e antigen (HBeAg), HAART 1 log from nadir), and viral blips. No TDF resistance was identified.Conclusions. Tenofovir/ emtricitabine was superior to other anti-HBV regimens in long-term HBV suppression. HBV viremia on therapy was identified in 1 of 3 main patterns. Suboptimal adherence was associated with detectable HBV DNA during therapy, even when HIV was undetectable. ? 2012 The Author",
author = "Gail Matthews and Seaberg, {Eric C} and Anchalee Avihingsanon and Scott Bowden and Dore, {Gregory J} and Lewin, {Sharon R} and Joe Sasadeusz and Peter Revill and Margaret Littlejohn and Hoy, {Jennifer F} and Robert Finlayson and Kiat Ruxrungtham and Melissa Saulynas and Stephen Locarnini and Thio, {Chloe L}",
year = "2013",
doi = "10.1093/cid/cit002",
language = "English",
volume = "56",
pages = "87 -- 94",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "9",

}

Matthews, G, Seaberg, EC, Avihingsanon, A, Bowden, S, Dore, GJ, Lewin, SR, Sasadeusz, J, Revill, P, Littlejohn, M, Hoy, JF, Finlayson, R, Ruxrungtham, K, Saulynas, M, Locarnini, S & Thio, CL 2013, 'Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus', Clinical Infectious Diseases, vol. 56, no. 9, pp. 87 - 94. https://doi.org/10.1093/cid/cit002

Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus. / Matthews, Gail; Seaberg, Eric C; Avihingsanon, Anchalee; Bowden, Scott; Dore, Gregory J; Lewin, Sharon R; Sasadeusz, Joe; Revill, Peter; Littlejohn, Margaret; Hoy, Jennifer F; Finlayson, Robert; Ruxrungtham, Kiat; Saulynas, Melissa; Locarnini, Stephen; Thio, Chloe L.

In: Clinical Infectious Diseases, Vol. 56, No. 9, 2013, p. 87 - 94.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus

AU - Matthews, Gail

AU - Seaberg, Eric C

AU - Avihingsanon, Anchalee

AU - Bowden, Scott

AU - Dore, Gregory J

AU - Lewin, Sharon R

AU - Sasadeusz, Joe

AU - Revill, Peter

AU - Littlejohn, Margaret

AU - Hoy, Jennifer F

AU - Finlayson, Robert

AU - Ruxrungtham, Kiat

AU - Saulynas, Melissa

AU - Locarnini, Stephen

AU - Thio, Chloe L

PY - 2013

Y1 - 2013

N2 - Background. Tenofovir (TDF) is effective for treatment of hepatitis B virus (HBV) in human immunodeficiency virus (HIV) infection; however, some individuals have ongoing HBV viremia, the reasons for which are unclear. We determined the patterns and factors associated with detectable HBV DNA in HIV-HBV-coinfected subjects on highly active antiretroviral therapy (HAART).Methods. One hundred sixty-five HIV-HBV-coinfected individuals from the United States, Australia, and Thailand, the majority of whom were on HAART at study entry, were prospectively followed semiannually for a median of 2.8 years. Logistic regression was used to determine factors associated with detectable HBV DNA.Results. Anti-HBV regimens were TDF/emtricitabine (57 ), lamivudine or emtricitabine (19 ), or TDF monotherapy (13 ). During follow-up, HBV DNA was detected at 21 of study visits and was independently associated with hepatitis B e antigen (HBeAg), HAART 1 log from nadir), and viral blips. No TDF resistance was identified.Conclusions. Tenofovir/ emtricitabine was superior to other anti-HBV regimens in long-term HBV suppression. HBV viremia on therapy was identified in 1 of 3 main patterns. Suboptimal adherence was associated with detectable HBV DNA during therapy, even when HIV was undetectable. ? 2012 The Author

AB - Background. Tenofovir (TDF) is effective for treatment of hepatitis B virus (HBV) in human immunodeficiency virus (HIV) infection; however, some individuals have ongoing HBV viremia, the reasons for which are unclear. We determined the patterns and factors associated with detectable HBV DNA in HIV-HBV-coinfected subjects on highly active antiretroviral therapy (HAART).Methods. One hundred sixty-five HIV-HBV-coinfected individuals from the United States, Australia, and Thailand, the majority of whom were on HAART at study entry, were prospectively followed semiannually for a median of 2.8 years. Logistic regression was used to determine factors associated with detectable HBV DNA.Results. Anti-HBV regimens were TDF/emtricitabine (57 ), lamivudine or emtricitabine (19 ), or TDF monotherapy (13 ). During follow-up, HBV DNA was detected at 21 of study visits and was independently associated with hepatitis B e antigen (HBeAg), HAART 1 log from nadir), and viral blips. No TDF resistance was identified.Conclusions. Tenofovir/ emtricitabine was superior to other anti-HBV regimens in long-term HBV suppression. HBV viremia on therapy was identified in 1 of 3 main patterns. Suboptimal adherence was associated with detectable HBV DNA during therapy, even when HIV was undetectable. ? 2012 The Author

UR - http://www.ncbi.nlm.nih.gov/pubmed/23315316

U2 - 10.1093/cid/cit002

DO - 10.1093/cid/cit002

M3 - Article

VL - 56

SP - 87

EP - 94

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 9

ER -